Collins Einhorn Farrell General and Automotive Liability Practice
ASCO G.U. 2014 Lawrence H. Einhorn. TOPICS Testis cancer – nothing new July 1, 2014 JCO...
-
Upload
trent-osmond -
Category
Documents
-
view
221 -
download
1
Transcript of ASCO G.U. 2014 Lawrence H. Einhorn. TOPICS Testis cancer – nothing new July 1, 2014 JCO...
TOPICS• Testis cancer – nothing new
• July 1, 2014 JCO (correspondence) – Albany and Einhorn: Pitfalls in low level elevations of AFP
• Bladder cancer
• PD-L1
• Renal cell cancer
• Ranking of treatment options
• Nivolumab PD-1
• Prostate cancer
• Adjuvant Docetaxel
• Enzalutamide
Inhibition of PD-L1 by MPDL3280A<br />leads to clinical activity in<br />patients with metastatic urothelial bladder cancer (UBC)
MPDL 3280A PD-L1 I IN METASTATIC BLADDER CA
• 65 patients entered
• 71% received 2 or more prior therapies
• 17 of 65 (26%) response rate, but 13 of 30 (43%) if PD-L1 positive (2+ or 3+) by IHC, including 2 C.R.s
• Genentech phase II study to enroll 326 (!!) patients
Nivolumab for metastatic renal cell <br />carcinoma (mRCC): results of a randomized, dose-ranging phase II trial
Presented By Robert Motzer at 2014 ASCO Annual Meeting
NIVOLUMAB IN METASTATIC RENAL CELL CA
• 168 patients entered; all received prior therapy and 70% 2 or more including VEGF TKIs (98%) MTOR inhibitors (38%) and immunotherapy (24%)
• 35 of 168 (21%) response rate; 19 of these 35 (54%) remissions were 12+ month duration
<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
E3805 – CHAARTED Treatment
Men with Metastatic Hormone Sensitive
Prostate Cancer
ADT + Docetaxel x 6 cycles
ADT Alone
ADT allowed up to 120 days prior to randomizationNo Intermittent ADT allowed
Primary Endpoint: Overall SurvivalSecondary Endpoints: PSA response rate, Time to progression, Toxicity QOL.
PREVAIL– Study Design
Men with Metastatic Castration
Resistant Prostate Cancer
Chemo-naïve N= 1717
EnzalutamideN=872
PlaceboN=845
Co-Primary Endpoint: Radiographic PFS Overall Survival
PREVAIL Was Halted at the Interim Analysis for Significant Benefit with Enzalutamide
Presented By Andrew Armstrong at 2014 ASCO Annual Meeting
Enzalutamide Prolonged Radiographic <br />Progression-Free Survival
Presented By Andrew Armstrong at 2014 ASCO Annual Meeting
Enzalutamide Delayed Time to PSA Progression
Presented By Andrew Armstrong at 2014 ASCO Annual Meeting